Comparison of a Travoprost BAK-Free Formulation Preserved with Polyquaternium-1 with BAK-Preserved Travoprost in Ocular Hypertension or Open-Angle Glaucoma
Restricted accessResearch articleFirst published online January, 2012
Comparison of a Travoprost BAK-Free Formulation Preserved with Polyquaternium-1 with BAK-Preserved Travoprost in Ocular Hypertension or Open-Angle Glaucoma
To demonstrate that the intraocular pressure (IOP)–lowering effect of travoprost 0.004% preserved with polyquaternium-1 (travoprost benzalkonium chloride [BAK]-free) is non-inferior to that of travoprost 0.004% preserved with benzalkonium chloride (travoprost BAK) in patients with ocular hypertension or open-angle glaucoma.
Methods
A total of 371 patients randomly received travoprost BAK-free (n=185) or travoprost BAK (n=186) dosed once daily in the evening for 3 months. Patients were evaluated at 9 AM, 11 AM, and 4 PM at baseline, weeks 2 and 6, and month 3. Intraocular pressure was also evaluated 36 and 60 hours after the month 3 visit.
Results
Travoprost BAK-free is non-inferior to travoprost BAK. The 95% upper confidence limits for the difference in mean IOP at month 3 (primary efficacy) were 0.5 mmHg, 0.6 mmHg, and 0.5 mmHg, at 9 AM, 11 AM, and 4 PM, respectively. Mean IOP reductions from baseline ranged from 7.6 to 8.7 mmHg in the travoprost BAK-free group and from 7.7 to 9.2 mmHg in the travoprost BAK group. At 36 and 60 hours after the last dose, mean IOP remained 6.8 mmHg and 5.7 mmHg below baseline in the travoprost BAK-free group, vs 7.3 mmHg and 6.0 mmHg in the travoprost BAK group, respectively. The safety profile of travoprost BAK-free was similar to that of travoprost BAK.
Conclusions
Travoprost BAK-free safely and effectively lowers IOP in eyes with open-angle glaucoma or ocular hypertension. This BAK-free formulation has comparable safety, efficacy, and duration of IOP-lowering effect to travoprost preserved with BAK. Travoprost BAK-free is an effective option for IOP reduction while avoiding BAK exposure.
FriedmanD.S., WolfsR.C., O'ColmainB.J., Eye Diseases Prevalence Research Group. Prevalenceof open-angle glaucoma among adults in the United States.Arch Ophthalmol2004; 122: 532–8.
2.
QuigleyH.A., BromanA.T.The number of people with glaucoma worldwide in 2010 and 2020.Br J Ophthalmol2006; 90: 262–7.
3.
KassM.A., HeuerD.K., HigginbothamE.J.The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.Arch Ophthalmol2002; 120: 701–13; discussion 829-30.
4.
HeijlA., LeskeM.C., BengtssonB., HymanL., BengtssonB., HusseinM. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.Arch Ophthalmol2002; 120: 1268–79.
5.
FellmanR.L., SullivanE.K., RatliffM., Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.Ophthalmology2002; 109: 998–1008.
6.
GrossR.L., PeaceJ.H., SmithS.E.Duration of IOP reduction with travoprost BAK-free solution.J Glaucoma2008; 17: 217–22.
7.
NetlandP.A., LandryT., SullivanE.K., Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol2001; 132: 472–84.
8.
Orengo-NaniaS., LandryT., Von TressM., SilverL.H., WeinerA., DavisA.A. Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.Am J Ophthalmol2001; 132: 860–8.
9.
de JongC., StolwijkT., KuppensE., de KeizerR., van BestJ.Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma.Graefes Arch Clin Exp Ophthalmol1994; 232: 221–4.
10.
IshibashiT., YokoiN., KinoshitaS.Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride.J Glaucoma2003; 12: 486–90.
11.
BaudouinC., LabbéA., LiangH., PaulyA., Brignole-BaudouinF.Preservatives in eyedrops: the good, the bad and the ugly.Prog Retin Eye Res2010; 29: 312–34.
PisellaP.J., DebbaschC., HamardP.Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.Invest Ophthalmol Vis Sci2004; 45: 1360–8.
14.
EpsteinS.P., ChenD., AsbellP.A.Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells.J Ocul Pharmacol Ther2009; 25: 415–24.
15.
KahookM.Y., NoeckerR.J.Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.Cornea2008; 27: 339–43.
16.
HorsleyM.B., KahookM.Y.Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.Clin Ophthalmol2009; 3: 291–5.
17.
KusanoM., UematsuM., KumagamiT., SasakiH., KitaokaT.Evaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivo.Cornea2010; 29: 80–5.
18.
UematsuM., KumagamiT., KusanoM.Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement method.Ophthalmic Res2007; 39: 308–14.
19.
BroadwayD.C., GriersonI., O'BrienC., HitchingsR.A.Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.Arch Ophthalmol1994; 112: 1446–54.
20.
YeeR.W.The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.Curr Opin Ophthalmol2007; 18: 134–9.
21.
ManniG., DenisP., ChewP.The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.J Glaucoma2009; 18: 293–300.
22.
TopouzisF., MelamedS., Danesh-MeyerH.A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.Eur J Ophthalmol2007; 17: 183–90.
23.
BreusegemC., SpielbergL., Van GinderdeurenR.Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial.Ophthalmology2010; 117: 1324–30.
24.
LeungE.W., MedeirosF.A., WeinrebR.N.Prevalence of ocular surface disease in glaucoma patients.J Glaucoma2008; 17: 350–5.
25.
AmmarD.A., NoeckerR.J., KahookM.Y.Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.Adv Ther2010; 27: 837–45.
26.
LiangH., Brignole-BaudouinF., PaulyA., RianchoL., BaudouinC.Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.Adv Ther2011; 28: 311–25.
27.
LewisR.A., KatzG.J., WeissM.J., Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.J Glaucoma2007; 16: 98–103.
28.
DubinerH.B., SircyM.D., LandryT.Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.Clin Ther2004; 26: 84–91.
29.
SitA.J., WeinrebR.N., CrowstonJ.G., KripkeD.F., LiuJ.H.Sustained effect of travoprost on diurnal and nocturnal intraocular pressure.Am J Ophthalmol2006; 141: 1131–3.
30.
García-FeijooJ., Martínez-de-la-CasaJ.M., CastilloA., MéndezC., Fernández-VidalA., García-SánchezJ.Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.Curr Med Res Opin2006; 22: 1689–97.
31.
LindénC., NuijaE., AlmA.Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension.Br J Ophthalmol1997; 81: 370–2.
32.
StewartW.C., HolmesK.T., JohnsonM.A.Washout periods for brimonidine 0.2% and latanoprost 0.005%.Am J Ophthalmol2001; 131: 798–9.
33.
AlmA., GriersonI., ShieldsM.B.Side effects associated with prostaglandin analog therapy.Surv Ophthalmol2008; 53(Suppl 1): S93–105.
34.
HonrubiaF., García-SánchezJ., PoloV., de la CasaJ.M., SotoJ.Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.Br J Ophthalmol2009; 93: 316–21.
